# OnCo record nct05985655 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05985655/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05985655", "NCT05985655" ;
  schema:name "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors"@en ;
  schema:alternateName "ELUCIDATE"@en ;
  schema:description "A phase 1/2 trial of GTAEXS617 in head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, HR-positive / HER2-negative breast cancer and triple-negative breast cancer, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05985655/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05985655> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-07-06" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:companies <https://onco.cc/companies/recursion/> .